• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌患者中PD-L1与Ki-67表达之间的关联及临床病理特征

Association between PD-L1 and Ki-67 expression and clinicopathologic features in NSCLC patients.

作者信息

Zhu Qing, Zhang Jingwen, Xu Derong, Zhao Rui

机构信息

Department of Clinical Laboratory, The First Affiliated Hospital of Nanchang University Nanchang, Jiangxi, China.

出版信息

Am J Transl Res. 2023 Aug 15;15(8):5339-5346. eCollection 2023.

PMID:37692968
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10492061/
Abstract

OBJECTIVE

To investigate the relationship between PD-L1, Ki-67 and the association between PD-L1, Ki-67, and clinicopathologic features and laboratory parameters in the peripheral blood of non-small cell lung cancer (NSCLC) patients.

METHODS

The clinical records of 213 NSCLC patients were retrospectively reviewed. The patients were divided into high or low expression groups by cut-off values of Ki-67 and PD-L1. Correlation of PD-L1 and Ki-67 expression were analyzed by linear regression analysis. The data were tested by Mann-Whitney test. Relationship of PD-L1 and Ki-67 was tested by chi-square test.

RESULTS

Linear regression analysis revealed a positive association between the expression of PD-L1 and Ki-67 (R=0.26, <0.001). The clinicopathologic features and laboratory parameters such as gender, smoking history, histological types, TNM stage, tumor size, ALB, and FIB were all significantly associated with PD-L1 and Ki-67 expression (all <0.05).

CONCLUSIONS

The expression of PD-L1 and Ki-67 is related to some clinicopathologic features and inflammatory factors, which brings new sight for exploiting combination biomarkers and therapeutic strategies.

摘要

目的

探讨非小细胞肺癌(NSCLC)患者外周血中程序性死亡受体配体1(PD-L1)、增殖细胞核抗原(Ki-67)之间的关系,以及PD-L1、Ki-67与临床病理特征和实验室参数之间的关联。

方法

回顾性分析213例NSCLC患者的临床记录。根据Ki-67和PD-L1的临界值将患者分为高表达组或低表达组。采用线性回归分析PD-L1和Ki-67表达的相关性。数据采用曼-惠特尼检验。采用卡方检验检测PD-L1与Ki-67的关系。

结果

线性回归分析显示PD-L1与Ki-67的表达呈正相关(R=0.26,P<0.001)。临床病理特征和实验室参数,如性别、吸烟史、组织学类型、TNM分期、肿瘤大小、白蛋白(ALB)和纤维蛋白原(FIB)均与PD-L1和Ki-67表达显著相关(均P<0.05)。

结论

PD-L1和Ki-67的表达与某些临床病理特征和炎症因子有关,这为开发联合生物标志物和治疗策略带来了新的视角。

相似文献

1
Association between PD-L1 and Ki-67 expression and clinicopathologic features in NSCLC patients.非小细胞肺癌患者中PD-L1与Ki-67表达之间的关联及临床病理特征
Am J Transl Res. 2023 Aug 15;15(8):5339-5346. eCollection 2023.
2
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.非小细胞肺癌患者血清来源外泌体中 PD-L1 表达的临床意义。
J Transl Med. 2019 Oct 29;17(1):355. doi: 10.1186/s12967-019-2101-2.
3
Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.PD-L1表达与中性粒细胞与淋巴细胞比值联合作为手术切除的非小细胞肺癌患者的预后标志物
J Cancer. 2019 Oct 22;10(26):6703-6710. doi: 10.7150/jca.34469. eCollection 2019.
4
Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.基于CT图像和临床病理特征的非小细胞肺癌中预测PD-L1表达的放射组学研究。
J Xray Sci Technol. 2020;28(3):449-459. doi: 10.3233/XST-200642.
5
PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.PD-L1 表达及其与非小细胞肺癌患者临床病理和基因组的相关性:印度视角。
Pathol Res Pract. 2021 Dec;228:153497. doi: 10.1016/j.prp.2021.153497. Epub 2021 May 24.
6
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.非小细胞肺癌中PD-L1表达与FDG PET/CT代谢参数及临床病理特征的相关性
EJNMMI Res. 2020 May 19;10(1):51. doi: 10.1186/s13550-020-00639-9.
7
Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.508例非小细胞肺癌患者术前血清CRP与PD-L1表达的相关性:全身炎症标志物的综合分析
Surg Oncol. 2018 Mar;27(1):88-94. doi: 10.1016/j.suronc.2018.01.002. Epub 2018 Jan 9.
8
Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.程序性死亡配体1(PD-L1)在肿瘤细胞或肿瘤浸润免疫细胞中的表达与实性和高级别肺腺癌相关。
Arch Pathol Lab Med. 2017 Nov;141(11):1529-1532. doi: 10.5858/arpa.2017-0028-OA. Epub 2017 Aug 22.
9
Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer.实验室参数与炎症相关,并不影响非小细胞肺癌中 PD-L1 的表达。
Anticancer Res. 2022 Mar;42(3):1563-1569. doi: 10.21873/anticanres.15630.
10
Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.非小细胞肺癌患者中PD-1、PD-L1和CTLA-4基因表达与临床病理特征的相关性
Clin Lung Cancer. 2017 Mar;18(2):e109-e116. doi: 10.1016/j.cllc.2016.09.010. Epub 2016 Oct 17.

引用本文的文献

1
Expression and clinical significance of CD155, FGL1, Galectin-9, and PD‑L1 in breast cancer with neoadjuvant chemotherapy.CD155、FGL1、半乳糖凝集素-9和PD-L1在新辅助化疗乳腺癌中的表达及临床意义
Med Oncol. 2025 Jul 25;42(9):375. doi: 10.1007/s12032-025-02914-y.
2
Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images.基于CT图像利用深度学习放射组学预测非小细胞肺癌患者的PD-L1状态。
Sci Rep. 2025 Apr 11;15(1):12495. doi: 10.1038/s41598-025-91575-y.
3
Expression of Programmed Cell Death-Ligand 1 (PD-L1) in Astrocytic Tumors and Its Correlation With Histopathological Grade and Proliferative Index (Ki-67): A Cross-Sectional Study.星形细胞瘤中程序性细胞死亡配体1(PD-L1)的表达及其与组织病理学分级和增殖指数(Ki-67)的相关性:一项横断面研究
Cureus. 2025 Feb 26;17(2):e79728. doi: 10.7759/cureus.79728. eCollection 2025 Feb.
4
Factors correlating the expression of PD-L1.与 PD-L1 表达相关的因素。
BMC Cancer. 2024 May 25;24(1):642. doi: 10.1186/s12885-024-12400-9.
5
Deep Learning to Predict the Cell Proliferation and Prognosis of Non-Small Cell Lung Cancer Based on FDG-PET/CT Images.基于FDG-PET/CT图像的深度学习预测非小细胞肺癌的细胞增殖和预后
Diagnostics (Basel). 2023 Sep 30;13(19):3107. doi: 10.3390/diagnostics13193107.

本文引用的文献

1
Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer.实验室参数与炎症相关,并不影响非小细胞肺癌中 PD-L1 的表达。
Anticancer Res. 2022 Mar;42(3):1563-1569. doi: 10.21873/anticanres.15630.
2
Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy.一线抗PD-1治疗联合铂类联合化疗的晚期非小细胞肺癌患者的治疗前纤维蛋白原-白蛋白比值(FAR)与治疗反应和生存相关。
Cancer Manag Res. 2022 Jan 26;14:377-386. doi: 10.2147/CMAR.S347547. eCollection 2022.
3
PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study.中国晚期非小细胞肺癌(NSCLC)患者的程序性死亡受体配体1(PD-L1)表达:一项多中心回顾性观察研究
J Cancer. 2021 Oct 28;12(24):7390-7398. doi: 10.7150/jca.63003. eCollection 2021.
4
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020.全球及中国癌症负担的变化趋势:对《2020年全球癌症统计数据》的二次分析
Chin Med J (Engl). 2021 Mar 17;134(7):783-791. doi: 10.1097/CM9.0000000000001474.
5
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.非小细胞肺癌中抗PD-1/PD-L1治疗的预测生物标志物。
Exp Hematol Oncol. 2021 Mar 2;10(1):18. doi: 10.1186/s40164-021-00211-8.
6
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?非小细胞肺癌(NSCLC)中PD-L1调控的机制:涉及哪些参与者?
Cancers (Basel). 2020 Oct 26;12(11):3129. doi: 10.3390/cancers12113129.
7
Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.PD1/PD-L1 免疫检查点抑制剂抗肿瘤耐药机制的研究与分析。
Cancer Med. 2020 Nov;9(21):8086-8121. doi: 10.1002/cam4.3410. Epub 2020 Sep 2.
8
Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy.非小细胞肺癌中的纳米医学:从传统治疗到免疫疗法
Cancers (Basel). 2020 Jun 18;12(6):1609. doi: 10.3390/cancers12061609.
9
PD-1/PD-L1 pathway: current researches in cancer.PD-1/PD-L1 通路:癌症领域的当前研究
Am J Cancer Res. 2020 Mar 1;10(3):727-742. eCollection 2020.
10
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer.程序性细胞死亡配体 1(PD-L1)在非鳞状非小细胞肺癌中的表达与临床病理和基因组学相关性。
Ann Oncol. 2020 Jun;31(6):807-814. doi: 10.1016/j.annonc.2020.02.017. Epub 2020 Apr 27.